In this issue:
Improved prognosis for stage III colon cancer
Worse OS with cetuximab in resectable colorectal liver metastases
Maintenance strategies in mCRC
First line folfoxiri plus bevacizumab then re-introduction after progression for metastatic CRC
TAS-102 +/- bevacizumab for chemorefractory mCRC
Regorafenib plus nivolumab in microsatellite stable colorectal cancer
Prognostic value of tumour deposits
ctDNA is a positive predictor for recurrence
R-spondin 2 gene polymorphism predicts FOLFIRI/bevacizumab outcome
Local vs total mesorectal excision
Please login below to download this issue (PDF)